Skip to content
PhageCocktails
PreclinicalProteus mirabilisTarget #29 of 50

Struvite stones & encrustation

Proteus mirabilis is the dominant cause of infection-type struvite urinary stones and of catheter encrustation and blockage in long-term catheterized patients. Its potent urease hydrolyzes urea, raising urine pH and driving precipitation of struvite and carbonate-apatite crystals that become embedded in a dense crystalline biofilm, occluding catheters and seeding recurrent stones. These crystalline biofilms are highly tolerant of antibiotics and shielded from host immunity, and there is currently no truly effective control method. Lytic bacteriophages are well suited here because they self-amplify at the infection site, can be matched to the colonizing strain, kill antibiotic-tolerant biofilm cells, and act independently of bacterial antibiotic resistance.

How phages act here

Mechanism

Anti-Proteus phages are strain-specific lytic viruses (podoviruses and myoviruses) that adsorb to surface receptors, replicate, and lyse the cell. Cocktails combine complementary phages to broaden host range across clinical isolates and to suppress resistance. By reducing the urease-producing population, phage treatment lowers urine pH and curtails struvite and apatite deposition rather than only killing planktonic cells. Many phages carry or induce depolymerases that degrade the biofilm matrix, enabling penetration of the crystalline layer, and have been paired with quorum-sensing interference to downregulate biofilm genes. Delivery is decisive: phages can be loaded into hydrogel catheter coatings or a pH-responsive smart coating that releases a therapeutic dose when rising urine pH signals incipient Proteus colonization, with engineered-phage and phage-antibiotic synergy as active extensions.

Where it stands

Current evidence

The evidence is robust but entirely preclinical and in vitro, with no completed or registered human clinical trial specific to P. mirabilis struvite stones or catheter encrustation as of 2026. The pivotal study (Nzakizwanayo et al., AAC 2016) used clinically realistic closed-drainage bladder models: a single dose of a 3-phage cocktail roughly tripled time-to-blockage in established infection and prevented blockage entirely when applied at early colonization, while significantly reducing crystalline biofilm. A pH-triggered phage-release catheter coating (Milo, Hathaway, Jenkins, J Mater Chem B 2017) doubled blockage time from 13 to 26 hours. Phage-coated catheters using the Melo and Sillankorva two-phage cocktail (Front Microbiol 2016) suppressed biofilm to 168 hours, a CDC dual-pathogen cocktail (Lehman and Donlan, AAC 2014) cut P. mirabilis biofilm by more than 2 log10 CFU per cm2, and the Isf-Pm1 and Isf-Pm2 cocktail (Mirzaei et al., Microbiol Spectr 2022) reduced biofilm mass about 65 percent. New biofilm-disrupting Proteus phages continued to be reported in 2025 and 2026, but translation is gated by manufacturing, dosing within the early-infection window, and the lack of indication-specific trials.

Evidence confidence: medium

The data

Key studies & trials

Who is working on it

Programs & centers

Jones and Jenkins groups, University of Brighton and University of Bath UKSillankorva and Azeredo group, University of Minho PortugalCDC Division of Healthcare Quality PromotionLavigne lab KU Leuven Belgium with Isfahan University of Medical Sciences IranNovolytics Ltd UK

The possibility

The most credible near-term product is a smart urinary catheter whose coating senses the pH spike of incipient Proteus colonization and releases a burst of strain-matched phages, turning catheter blockage from an inevitability into a preventable event and sparing patients obstruction, sepsis, and repeat stone surgery. Because phages lower urine pH at the source, the same cocktails could be instilled into the bladder to undercut struvite stones before they grow, complementing antibiotics that crystalline biofilms routinely defeat. With strain-banked broad-host-range cocktails and depolymerase-armed engineered phages advancing, a personalized phage-on-demand approach to chronic catheter and stone disease is within scientific reach, awaiting dedicated clinical trials.

Scientific & educational content. As of 2026 no bacteriophage therapeutic is approved as a marketed drug in the United States or European Union. Phage therapy is available only through clinical trials, compassionate-use / expanded-access pathways, and national magistral frameworks. Nothing here is medical advice or an offer to sell a therapeutic.